Table 3.

Drugs with significant enrichment to diurnal signature in the Connectivity Map

rank	drug	mean	n	p-value
1	sirolimus	0.68	10	0
2	LY-294002	0.54	17	0
3	wortmannin	0.62	8	0.0001
4	trichostatin A	0.48	12	0.0012
5	resveratrol	0.61	5	0.0026
6	5182598	-0.78	2	0.0043
7	estradiol	-0.39	10	0.0079
8	iloprost	-0.71	3	0.0105
9	tacrolimus	-0.56	3	0.0153
10	arachidonyltrifluoromethane	-0.75	2	0.02
11	deferoxamine	0.49	3	0.0292
12	fludrocortisone	-0.60	2	0.0429
13	quercetin	-0.53	2	0.0607
14	TTNPB	-0.57	2	0.0645
15	vorinostat	0.53	2	0.0734
16	fulvestrant	0.39	7	0.0858
17	raloxifene	-0.15	3	0.0876
18	rottlerin	0.43	3	0.0945

The drugs with significant connectivity to the diurnal signature are ranked in the order of significance of the connectivity score as judged by the permutation p-value (column labeled "p-value"). Significance cut-off was set at pvalue = 0.1. The permutation p-value estimates the likelihood that the enrichment of a given set of post-dose gene expression changes (instances) by a given drug, relative to all available post-dose changes in the CMAP database (for all drugs) would be observed by random chance. Mean: the arithmetic mean of the connectivity scores for the post-dose changes by the given drug; N: the number of instances of a given drug in CMAP database[23].